Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – IT Business Net
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine…
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2,…
-
Noosa News16 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business21 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Business19 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
General22 hours agoRush to buy homes before rate cuts send prices soaring